Tianjin Pharmaceutical Da Ren Tang Group600329.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Richly Valued” zone.
As of Oct 19, 2026, Tianjin Pharmaceutical Da Ren Tang Group (600329.SH) trades at a P/E of 33.80x, P/B of 4.83x, P/S of 5.84x, and a dividend yield of 12.88%.
Longitudinal percentile comparison: P/E sits at the 98th percentile over the trailing 10Y window (vs. 100th percentile over 3Y); P/B sits at the 96th percentile over the trailing 10Y window (vs. 96th percentile over 3Y); P/S sits at the 94th percentile over the trailing 10Y window (vs. 80th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 46th percentile within its industry and the 46th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 12.88%, ranking at the 98th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 1.5 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Tianjin Pharmaceutical Da Ren Tang Group operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 600329 · SSE: 600329 · 600329
Want the full picture on whether Tianjin Pharmaceutical Da Ren Tang Group (600329.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 33.80 | ||||||
| P/B (MRQ) | 4.83 | ||||||
| P/S (TTM) | 5.84 | ||||||
| Dividend Yield | 12.88% | ||||||
| Buyback + Div Yield | 12.88% |